Left Atrial Appendage (LAA) Occluders

This channel includes news and new technology innovations about Left Atrial Appendage (LAA) Occluders. These close off the LAA in patients with atrial fibrillation to prevent the formation of stroke-causing clots in atrial fibrillation (AFib or AF) patients. LAA occlusion is often indicated for patients who do not tolerate anticoagulation therpy or have bleeding risks associated with use of that therapy.

The Abbott Amplatzer Amulet left atrial appendage (LAA) transcatheter occlusion device. It received FDA clearance in August 2021. #LAA

News | Left Atrial Appendage (LAA) Occluders

FDA Clears Abbott Amplatzer Amulet LAA Occluder to Reduce Stroke in People With Atrial Fibrillation

August 16, 2021 — The U.S. Food and Drug Administration (FDA) approved Abbott's Amplatzer Amulet Left Atrial Appendage ...

August 16, 2021

ast End Medical announced it received U.S. Food and Drug Administration (FDA) clearance for the company's SafeCross Transseptal Radiofrequency (RF) Puncture and Steerable Balloon Introducer System. The 3-in-1 system, which includes a steerable introducer sheath with an ultra-visible positioning balloon and radiofrequency (RF) puncture dilator, aims to provide a predictable and safe solution for electrophysiology (EP) and structural heart interventions requiring left atrial access.

News | Cath Lab

FDA Clears SafeCross Transseptal RF Puncture and Steerable Balloon Introducer System

July 13, 2021 — East End Medical announced it received U.S. Food and Drug Administration (FDA) clearance for the company ...

July 14, 2021

CentraCare completed the first structural heart procedure in the world guided by a new 4-D hologram technology developed by EchoPixel. The augmented reality technology aims to reduce reduce procedure time, improve accuracy of the procedure, and reduce risk of complications.

Feature | Virtual and Augmented Reality

First 4D Hologram Guided Structural Heart Procedure Performed for LAA Occlusion

June 28, 2021 — CentraCare, one of the largest health systems in Minnesota, successfully completed the first structural ...

June 28, 2021

The Boston Scientific Watchman device have performed better than expected in real-world patients outside of trials since it was introduced in 2015, according to data from the NCDR LAAO Registry. #ACC21 #ACC2021 #LAA #Watchman

Feature | Left Atrial Appendage (LAA) Occluders

NCDR LAAO Registry Shows Left Atrial Appendage Occlusion Associated With Low Rate of Stroke

May 15, 2021 - Transcatheter left atrial appendage occlusion (LAAO) with a Boston Scientific Watchman device was ...

May 16, 2021

In the LAAOS III trial, surgeons could seal off the LAA during the open heart procedure using sutures, staples or approved closure devices. The image shows a SentraHeart lasso type LAA occluder about to seal off the LAA from the outside of the heart. #ACC21 #ACC2021

News | Left Atrial Appendage (LAA) Occluders

Left Atrial Appendage Occlusion Reduces Stroke After Heart Surgery

May 15, 2021 — Patients with an elevated risk of stroke due to heart rhythm problems, or atrial fibrillation (AFib) ...

May 15, 2021

Transesophageal echo (TEE) being used to guide the deployment of a MitraClip device during a transcatheter structural heart procedure in the hybrid lab at the University of Colorado Hospital. The center has performed more than 200 MitraClip mitral valve repairs over the past decade. Photo by Dave Fornell

Blog | Structural Heart

Creating a Structural Heart Program is an Investment in the Future of the Hospital

As a medical technology journalist, a little more than a decade ago I found myself sitting in those late afternoon ...

April 21, 2021

The Teleflex Manta large-bore vascular closure device can seal holes between 12 and 25 French.

Feature | Hemostasis Management | Dave Fornell, Editor

Large Bore Closure in Structural Heart Interventions

While many cardiac and vascular procedures have largely moved to minimally invasive techniques, the size of these ...

March 09, 2021

AMERICAN COLLEGE OF CARDIOLOGY (ACC) Late-breaking clinical trial study presentations at ACC.21. @ACC21 @ACC2021

Feature | ACC | Dave Fornell, Editor

ACC 2021 Late Breaking Cardiology Study Results

The latest cardiology practice-changing scientific breakthrough, late-breaking study presentations have been announced ...

May 18, 2021

The Watchman FLX will be tested in the CHAMPION-AF trial looks at next-generation transcatheter LAA device as treatment alternative to NOACs for broader population of patients with non-valvular atrial fibrillation.

News | Atrial Fibrillation

Boston Scientific Initiates Trial to Evaluate Watchman FLX LAA Closure Device as First-Line Treatment

Oct. 29, 2020 — Boston Scientific initiated the CHAMPION-AF clinical trial to evaluate the safety and efficacy of the ...

October 29, 2020

Positive clinical data from first-in-human studies of the Conformal Medical left atrial appendage closure (LAAC) CLAAS device performed in the U.S. and Prague were presented at 2020 Transcatheter Cardiovascular Therapeutics (TCT) Connect virtual meeting. Two two abstracts were presented by William Gray, M.D., from Lankenau Heart Institute, Wynnewood, Penn., and Vivek Reddy, M.D., from Mount Sinai Hospital in New York. #TCT2020 #TCTconnect

News | Left Atrial Appendage (LAA) Occluders

Conformal Medical CLAAS LAA Occluder Shows Promising Clinical Results at TCT 2020

October 16, 2020 — Positive clinical data from first-in-human studies of the Conformal Medical left atrial appendage ...

October 16, 2020

Flexible electronics have been developed to implant in patients to constantly monitor their cardiac condition.

Feature | Udi Nussinovitch M.D., Ph.D.

What is New in Cardiology? A Review of All Major Emerging Technologies for Heart Diseases

This is an overview of some of the biggest cardiology technology advances. These innovations are covered in more detail ...

October 09, 2020

Videos | Left Atrial Appendage (LAA) Occluders

VIDEO: Overview of Left Atrial Appendage (LAA) Closure Technology and New Innovations

Horst Sievert, M.D., is the director of the Cardiovascular Center Frankfurt, and associate professor of internal ...

October 02, 2020

Boston Scientific recently introduced the newst iteration of LAA occluder device, the Watchman FLX. It uses small spikes to help better anchor the device and prevent embolization.

News | Left Atrial Appendage (LAA) Occluders

COVID-19 Boosts Demand for Left Atrial Appendage Closure Devices Market

August 21, 2020 — According to a report published by Research Dive, the rising number of patients suffering from atrial ...

August 21, 2020

The Conformal Medical CLAAS device, a next-generation transcatheter left atrial appendage (LAA) closure occluder for patients with atrial fibrillation (AF). LAA occlusion allows AFib patients to go off of life-long anticoagulation therapy. #LAA #LAAC

News | Left Atrial Appendage (LAA) Occluders

Conformal Medical Secures $85 Million in Funding for Left Atrial Appendage Occluder Trial

August 6, 2020 – Conformal Medical Inc. announced it secured $85 million in Series C financing to support the company’s ...

August 06, 2020

Two of the top pieces of content in July included the FDA clearance for the new Watchman FLX left atrial appendage occluder (left), which includes a video interview with one of the trial investigators. COVID-19 content remained among the top content in July, and one story explained the odd pattern of cardiac cell death in COVID-19 patient autopsies.

Feature | Dave Fornell, Editor

August 3, 2020 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) mag ...

August 03, 2020